search
Back to results

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Primary Purpose

Breast Cancer, Triple Negative Breast Cancer

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
olaparib
Sponsored by
Istituti Ospitalieri di Cremona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer focused on measuring olaparib

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures
  2. Patients (female) must be 18 years of age.
  3. Clinically or radiologically measurable or evaluable disease defined as: presence of bidimensionally or unidimensionally measurable breast lesion by physical or radiological examination.
  4. Estrogen receptor < 10% for ARM A only
  5. Progesterone receptor = 0 for ARM A only
  6. HER2 negative on primary tumor (HER-2 score of 0 or 1+/2+ with FISH not amplified) for ARM A only
  7. Mutation of BRCA 1 and/or 2 for ARM B only

    • Germline BRCA1 or BRCA2 mutation that is considered deleterious or suspected deleterious (include those mutations or translocations termed "deleterious" or "suspected deleterious" according to lab reporting). Testing under the context of this protocol may be performed at any time prior to allocation.
    • Patients who have a prior BRCA test may be enrolled into the study based at the result of the prior test
    • Provision of informed consent for genetic research. If a patient declines to participate in the genetic research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to that part.
  8. Patients must have normal organ and bone marrow function, ECOG performance status 0-1 (can be amended for specific populations studies)
  9. Adequate cardiac function: left ventricular ejection fraction (LVEF) at rest measured by echocardiography must be no lower than the local normal limit.
  10. Absence of clinically significant cardiovascular disease (e.g. myocardial infarction, unstable angina), New York Hearth Association (NYHA) grade II or greater congestive hearth failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 12 months prior to day 1 on study
  11. Patients must have voluntarily agreed to participate by given informed consent. Written informed consent must be dated and signed by both patients and investigator

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  2. Previous enrolment in the present study
  3. Participation in another clinical study with an investigational product during the last 12 months
  4. Any previous treatment with a PARP inhibitor, including olaparib.
  5. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug.
  6. Concomitant use of known CYP3A4 inhibitors such as ketokonazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir
  7. Blood transfusions within 1 month prior to study start
  8. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  9. Patients with-out any sign or symptoms of distant metastases.
  10. Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Olaparib triple negative

    Olaparib BRCA mutated

    Arm Description

    Olaparib short administration in triple negative breast cancer

    Olaparib short administration in BRCA mutated patients

    Outcomes

    Primary Outcome Measures

    Correlation between baseline gene and protein expression profile and clinical response

    Secondary Outcome Measures

    Assess overall response rate by RECIST criteria evaluated clinically in each treatment group
    Evaluate safety and tolerability of olaparib alone assessed by CTCAE v4.0
    Compare time to deterioration of health-related quality of life by QLQ-C30 scale
    Compare health status by QLQ-C30 scale

    Full Information

    First Posted
    February 8, 2016
    Last Updated
    February 12, 2016
    Sponsor
    Istituti Ospitalieri di Cremona
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02681562
    Brief Title
    Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
    Official Title
    A Phase II, Open Label, Controlled Study of Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients: Biological Evaluation From a "Window of Opportunity" Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    January 2016 (undefined)
    Primary Completion Date
    January 2018 (Anticipated)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Istituti Ospitalieri di Cremona

    4. Oversight

    5. Study Description

    Brief Summary
    Treatment selection for breast cancer is still largely empiric and guided by large randomized clinical trials on populations of patients. This approach is inadequate for the selection of individualized chemotherapy regimens. Estimates of benefits for individuals are extrapolations from the effects seen in these large trials, and do not necessarily apply to individual patients. The revolution in genomics promises to transform oncology care. By better defining cancer subtypes, a better understanding of breast cancer biology should help to guide treatment. The up-front phase we have decide to adopt play a pivotal role as it is useful for testing a targeted therapeutic drug such as olaparib wich also requires development of new biomarkers which may be useful for future studies. With this approach it could be possible to demonstrate drug target or biomarker effect in clinical setting and models the relationship between the pharmacodynamics and the pharmacokinetics. Additional benefits of this approach include the following: It could facilitate rational drug selection, identify therapeutic failures early, and compress timelines for anticancer drug development. It could provide initial rationale and guiding principles for further drug development based on studies in humans (rather than xenografts, where tissues of one species are transplanted to another species). As it focuses on extensively characterizing how a drug works and whether it hits its intended target (including molecular imaging studies) in a limited number of patients it could yield results that would optimally inform and expedite the subsequent development of molecularly-targeted agents

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Breast Cancer, Triple Negative Breast Cancer
    Keywords
    olaparib

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    45 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Olaparib triple negative
    Arm Type
    Experimental
    Arm Description
    Olaparib short administration in triple negative breast cancer
    Arm Title
    Olaparib BRCA mutated
    Arm Type
    Experimental
    Arm Description
    Olaparib short administration in BRCA mutated patients
    Intervention Type
    Drug
    Intervention Name(s)
    olaparib
    Primary Outcome Measure Information:
    Title
    Correlation between baseline gene and protein expression profile and clinical response
    Time Frame
    Duration of the study
    Secondary Outcome Measure Information:
    Title
    Assess overall response rate by RECIST criteria evaluated clinically in each treatment group
    Time Frame
    Through study completion, an average of 1 year
    Title
    Evaluate safety and tolerability of olaparib alone assessed by CTCAE v4.0
    Time Frame
    Through study completion, an average of 1 year
    Title
    Compare time to deterioration of health-related quality of life by QLQ-C30 scale
    Time Frame
    Through study completion, an average of 1 year
    Title
    Compare health status by QLQ-C30 scale
    Time Frame
    Through study completion, an average of 1 year

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Provision of informed consent prior to any study specific procedures Patients (female) must be 18 years of age. Clinically or radiologically measurable or evaluable disease defined as: presence of bidimensionally or unidimensionally measurable breast lesion by physical or radiological examination. Estrogen receptor < 10% for ARM A only Progesterone receptor = 0 for ARM A only HER2 negative on primary tumor (HER-2 score of 0 or 1+/2+ with FISH not amplified) for ARM A only Mutation of BRCA 1 and/or 2 for ARM B only Germline BRCA1 or BRCA2 mutation that is considered deleterious or suspected deleterious (include those mutations or translocations termed "deleterious" or "suspected deleterious" according to lab reporting). Testing under the context of this protocol may be performed at any time prior to allocation. Patients who have a prior BRCA test may be enrolled into the study based at the result of the prior test Provision of informed consent for genetic research. If a patient declines to participate in the genetic research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to that part. Patients must have normal organ and bone marrow function, ECOG performance status 0-1 (can be amended for specific populations studies) Adequate cardiac function: left ventricular ejection fraction (LVEF) at rest measured by echocardiography must be no lower than the local normal limit. Absence of clinically significant cardiovascular disease (e.g. myocardial infarction, unstable angina), New York Hearth Association (NYHA) grade II or greater congestive hearth failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 12 months prior to day 1 on study Patients must have voluntarily agreed to participate by given informed consent. Written informed consent must be dated and signed by both patients and investigator Exclusion Criteria: Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) Previous enrolment in the present study Participation in another clinical study with an investigational product during the last 12 months Any previous treatment with a PARP inhibitor, including olaparib. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug. Concomitant use of known CYP3A4 inhibitors such as ketokonazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir Blood transfusions within 1 month prior to study start Patients with myelodysplastic syndrome/acute myeloid leukaemia. Patients with-out any sign or symptoms of distant metastases. Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    27324108
    Citation
    Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial. Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21.
    Results Reference
    derived

    Learn more about this trial

    Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

    We'll reach out to this number within 24 hrs